Pfizer: Post-Surgical Pain Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Taiwan Liposome Company, Teikoku Pharma USA, Durect, Pfizer, Vivozon, Salvat Laboratories, Vertex Pharma

The Key Post-Surgical Pain Companies in the market include - Ocular Therapeutix, Heron Therapeutics, Avenue Therapeutics, Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others. DelveInsight's "Post-Surgical Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Post-Surgical Pain, historical and forecasted epidemiology as well as the Post-Surgical Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Post-Surgical Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Post-Surgical Pain Market Forecast Some of the key facts of the Post-Surgical Pain Market Report: The Post-Surgical Pain market size is anticipated to grow with a significant CAGR during the study period (2019-2032) In February 2025, Allay Therapeutics, a clinical-stage biotechnology company focused on ultra-sustained analgesic solutions for post-surgical pain management, has announced the dosing of the first patient in its Phase 2b registration trial evaluating ATX101 for post-surgical pain relief following total knee replacement (TKA) surgery. ATX101, a novel investigational analgesic, aims to deliver long-lasting pain relief, minimizing opioid dependence and enhancing patient recovery. In January 2024, Taiwan-based Xgene Pharmaceutical reported positive results from its Phase IIb study evaluating XG005, a non-opioid analgesic, for post-surgical acute pain relief. The placebo-controlled, dose-ranging trial (NCT06017999) assessed pain reduction using the summed pain index (SPI) over 48 hours following bunionectomy surgery. The study compared two doses of XG005 (1,250 mg and 750 mg) against a placebo to determine its efficacy. In November 2024, Averitas Pharma, the U.S. subsidiary of Grünenthal, has successfully completed patient enrollment for its Phase III AV001 clinical trial, evaluating QUTENZA (capsaicin) 8% topical system for the treatment of post-surgical neuropathic pain (PSNP). Several leading Post-Surgical Pain companies are advancing their key drug candidates through various stages of clinical development, including IV Tramadol by Avenue Therapeutics, Opiranserin (VVZ-149) Injections by Vivozon, OCS-01 by Oculis, among others. In 2023, the 7MM recorded approximately 67 million incident cases of Post-Surgical Pain. This number is projected to rise by 2032, driven by an increase in traffic accidents, trauma-related injuries, and the growing demand for pain management after surgeries. In 2023, the US accounted for the highest proportion of incident Post-Surgical Pain cases, contributing approximately 60.41% of the total cases in the 7MM. Meanwhile, EU4 and the UK represented around 21.14%, while Japan accounted for approximately 18.43% of the total cases. As per DelveInsight, in 2023, the estimated severity-specific incident cases of Post-Surgical Pain in France were approximately 1.2 million mild cases, 1.5 million moderate cases, and 0.8 million severe cases. These numbers are projected to rise by 2032 due to an increasing incidence of Post-Surgical Pain. In 2023, the estimated severity-specific incident cases of Post-Surgical Pain in Germany were approximately 1.4 million mild cases, 1.7 million moderate cases, and 1 million severe cases. These figures are projected to rise throughout the forecast period (2023-2032). In the UK, around 4,050,000 new cases of Post-Surgical Pain were reported in 2023. Key Post-Surgical Pain Companies: Ocular Therapeutix, Heron Therapeutics, Avenue Therapeutics, Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others Key Post-Surgical Pain Therapies: DEXTENZA (dexamethasone), ZYNRELEF (bupivacaine and meloxicam), IV Tramadol, TLC590, TPU-006, CA-008, SVT-15473, VX-548, OCS-01, N1539, SHR0410, Ketorolac tromethamine, AYX1, EXPAREL, Toragesic®, SABER-Bupivacaine, lyrica, VVZ-149, Tapentadol (OS), Percocet, YM177, LMX4, and others The Post-Surgical Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Post-Surgical Pain pipeline products will significantly revolutionize the Post-Surgical Pain market dynamics. The Post-Surgical Pain market size is anticipated to grow with a significant CAGR during the study period (2019-2032) In February 2025, Allay Therapeutics, a clinical-stage biotechnology company focused on ultra-sustained analgesic solutions for post-surgical pain management, has announced the dosing of the first patient in its Phase 2b registration trial evaluating ATX101 for post-surgical pain relief following total knee replacement (TKA) surgery. ATX101, a novel investigational analgesic, aims to deliver long-lasting pain relief, minimizing opioid dependence and enhancing patient recovery. In January 2024, Taiwan-based Xgene Pharmaceutical reported positive results from its Phase IIb study evaluating XG005, a non-opioid analgesic, for post-surgical acute pain relief. The placebo-controlled, dose-ranging trial (NCT06017999) assessed pain reduction using the summed pain index (SPI) over 48 hours following bunionectomy surgery. The study compared two doses of XG005 (1,250 mg and 750 mg) against a placebo to determine its efficacy. In November 2024, Averitas Pharma, the U.S. subsidiary of Grünenthal, has successfully completed patient enrollment for its Phase III AV001 clinical trial, evaluating QUTENZA (capsaicin) 8% topical system for the treatment of post-surgical neuropathic pain (PSNP). Several leading Post-Surgical Pain companies are advancing their key drug candidates through various stages of clinical development, including IV Tramadol by Avenue Therapeutics, Opiranserin (VVZ-149) Injections by Vivozon, OCS-01 by Oculis, among others. In 2023, the 7MM recorded approximately 67 million incident cases of Post-Surgical Pain. This number is projected to rise by 2032, driven by an increase in traffic accidents, trauma-related injuries, and the growing demand for pain management after surgeries. In 2023, the US accounted for the highest proportion of incident Post-Surgical Pain cases, contributing approximately 60.41% of the total cases in the 7MM. Meanwhile, EU4 and the UK represented around 21.14%, while Japan accounted for approximately 18.43% of the total cases. As per DelveInsight, in 2023, the estimated severity-specific incident cases of Post-Surgical Pain in France were approximately 1.2 million mild cases, 1.5 million moderate cases, and 0.8 million severe cases. These numbers are projected to rise by 2032 due to an increasing incidence of Post-Surgical Pain. In 2023, the estimated severity-specific incident cases of Post-Surgical Pain in Germany were approximately 1.4 million mild cases, 1.7 million moderate cases, and 1 million severe cases. These figures are projected to rise throughout the forecast period (2023-2032). In the UK, around 4,050,000 new cases of Post-Surgical Pain were reported in 2023. Key Post-Surgical Pain Companies: Ocular Therapeutix, Heron Therapeutics, Avenue Therapeutics, Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others Key Post-Surgical Pain Therapies: DEXTENZA (dexamethasone), ZYNRELEF (bupivacaine and meloxicam), IV Tramadol, TLC590, TPU-006, CA-008, SVT-15473, VX-548, OCS-01, N1539, SHR0410, Ketorolac tromethamine, AYX1, EXPAREL, Toragesic®, SABER-Bupivacaine, lyrica, VVZ-149, Tapentadol (OS), Percocet, YM177, LMX4, and others The Post-Surgical Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Post-Surgical Pain pipeline products will significantly revolutionize the Post-Surgical Pain market dynamics. Post-Surgical Pain Overview Post-Surgical Pain is discomfort or pain experienced after a surgical procedure due to tissue trauma, nerve damage, or inflammation. It can be acute (short-term) or chronic (lasting beyond the normal healing period, usually over three months). Pain levels vary based on the type of surgery, individual pain tolerance, and pre-existing conditions. Management includes medications (opioids, NSAIDs, local anesthetics), physical therapy, and nerve blocks to enhance recovery and prevent complications. Proper pain control is crucial to improving patient outcomes and reducing the risk of chronic pain development. Get a Free sample for the Post-Surgical Pain Market Report: https://www.delveinsight.com/report-store/post-surgical-pain-market Post-Surgical Pain Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Post-Surgical Pain Epidemiology Segmentation: The Post-Surgical Pain market report proffers epidemiolog